Fixed-dose combinations in the management of hypertension: Defining the place of angiotensin receptor antagonists and hydrochlorothiazide

American Journal of Cardiovascular Drugs

Volumn 5, Issue 1, 2005, Pages 17-22

  Kjeldsen, Sverre E ^a,b   Os, Ingrid ^a,c   Høieggen, Aud ^a   Beckey, Kim ^d   Gleim, Gilbert W ^d   Oparil, Suzanne ^e  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF OSLO   (Norway)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN HEXETIL; CHLOROTHIAZIDE DERIVATIVE; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; COGNITION; COUGHING; DIABETES MELLITUS; DIZZINESS; DRUG DOSAGE FORM; DRUG MECHANISM; DRUG POTENTIATION; GLUCOSE INTOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 12744263227     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200505010-00003     Document Type: Review

References (33)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003; 289: 2560-71
2. Amer J. Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK study). J Hypertens 2002; 20: 779-84
3. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA 2002; 288: 2981-97
4. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003
5. European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension: Guidelines Committee 2003. J Hypertens 2003; 6: 1011-53
6. Mudge GH. Diuretics and other agents employed in the mobilization of edema fluid. In: Gilman AG, Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. New York: Macmillan Publishing Co, 1980: 892-915
7. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4-9
8. Goth A. Diuretic drugs. In: Goth A, editor. Medical pharmacology. St Louis: CV Mosby, 1978: 426-44
9. Weiner IM, Mudge GH. Diuretics and other agents employed in the mobilization of edema fluid. In: Gilman AG, Goodman LS, Rall TW, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Macmillan Publishing Co, 1985: 895
10. Roberts CJ, Marshall AJ, Heaton S, et al. Comparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and spironolactone. BMJ 1979; 1: 224-6
11. Gibbs CR, Beevers DG. Angiotensin receptor antagonism with losartan and the regression of left ventricular hypertrophy. J Hum Hypertens 1998; 12: 493-5
12. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9
13. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60
14. Hasser EM, Cunningham JT, Sullivan MJ, et al. Area postrema and sympathetic nervous system effects of vasopressin and angiotensin II. Clin Exp Pharmacol Physiol 2000; 27: 432-6
15. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-{gamma} activity. Circulation 2004; 109: 2054-7
16. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study: ELITE II. Lancet 2000; 355: 1582-7
17. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752-60
18. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure: the Valsartan Heart Failure Trial Investigators. N Engl J Med 2001; 345: 1667-75
19. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906
20. Julius PS, Kjeldsen PS, Weber PM, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31
21. Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86
22. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66
23. Hall J, Marbury T, Gray J, et al. Long term safety, tolerability and efficacy of valsartan: results from one and two year trials. J Clin Res 1998; 1: 147-59
24. Goldberg AI, Dunlay MC, Sweet CS. Safety of losartan. Am J Cardiol 1995; 75: 793-5
25. Laragh J. Laragh's lessons in renin system pathophysiology for treating hypertension and its fatal cardiovascular consequences. New York: Elsevier, 2002
26. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-74
27. Elliott WJ, Calhoun DA, DeLucca PT, et al. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001; 23: 1166-79
28. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-9
29. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-26
30. Chrysant SG, Weber MA, Wang A, et al. Factorial design to assess the safety and efficacy of olmesartan medoxomil and hydrochlorothiazide combination therapy. Am J Hypertens 2003; 16: 110A-1A
31. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833-50
32. Sachse A, Verboom CN, Jäger B. Efficacy of eprosartan in combination with hydrochlorothiazide in patients with essential hypertension. J Hum Hypertens 2002; 16: 169-76
33. Dahlof B, Devereux RB, Kjeldsen SE. Diuretics in the LIFE study [letter]. Lancet 2004. 364: 413-4